![]() |
市场调查报告书
商品编码
1684650
CAR-T 细胞疗法市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测CAR T-cell Therapy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
2024 年全球 CAR-T 细胞疗法市场价值为 43 亿美元,预计将经历强劲的成长轨迹,2025 年至 2034 年的复合年增长率将达到 30.5%。嵌合抗原受体 (CAR) T 细胞疗法正在彻底改变癌症治疗,标誌着肿瘤学的一个重要里程碑。这种先进的免疫疗法涉及对患者 T 细胞进行基因改造,以便更好地瞄准和消灭癌细胞。 CAR T 细胞疗法不仅为患者带来了新的希望,也改变了我们治疗某些癌症的方式。随着技术的日益普及和进步,这个市场有望不断扩张。
全球市场分为几种主要产品,包括 Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta 等。其中,Yescarta脱颖而出,成为市场领导者,2024年占了32.5%的市占率。 Yescarta占据市场主导地位的主要原因在于它对B细胞淋巴瘤患者已被证明有效,特别是在传统治疗方法往往无效的复发或难治性病例中。随着越来越多的患者寻求治疗恶性癌症的替代疗法,对 Yescarta 的需求持续增长,进一步巩固了其在该领域的领先地位。
市场范围 | |
---|---|
起始年份 | 2024 |
预测年份 | 2025-2034 |
起始值 | 43亿美元 |
预测值 | 611亿美元 |
复合年增长率 | 30.5% |
从适应症来看,CAR-T 细胞治疗市场分为白血病、淋巴瘤、多发性骨髓瘤等,其中淋巴瘤的收入最高,2024 年将达到 24 亿美元。瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是一种常见的非何杰金氏淋巴瘤,是这一增长的主要贡献者。 DLBCL 在接受传统疗法治疗后復发率较高,这推动了对 CAR T 细胞疗法的需求,这种疗法在针对和治疗侵袭性淋巴瘤方面表现出了显着的疗效。因此,CAR-T 细胞疗法越来越被视为治疗这些棘手癌症类型的重要解决方案,为别无选择的患者带来了新的希望。
预计到 2034 年,美国 CAR-T 细胞疗法市场规模将达到 250 亿美元,在支持性监管框架的推动下,市场将实现强劲成长。美国食品药物管理局(FDA)在 CAR-T 细胞疗法的快速开发和商业化中发挥了关键作用,透过突破性疗法认定、孤儿药地位和快速通道等加速审批流程提供关键的监管支持。这些措施加速了CAR-T细胞疗法的普及,确保需要救命治疗的患者能够及时获得治疗。
The Global CAR T-Cell Therapy Market, valued at USD 4.3 billion in 2024, is projected to experience a robust growth trajectory, with an impressive CAGR of 30.5% from 2025 to 2034. Chimeric Antigen Receptor (CAR) T-cell therapy is revolutionizing cancer treatment, marking a significant milestone in oncology. This advanced form of immunotherapy involves the genetic modification of a patient's T-cells to better target and eliminate cancer cells. CAR T-cell therapy is not only offering new hope for patients but also changing the way we approach the treatment of certain cancers. With its growing adoption and advancements in technology, this market is poised for continuous expansion.
The global market is divided into several key products, including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and others. Among these, Yescarta stands out as the market leader, capturing 32.5% of the total market share in 2024. The primary reason for Yescarta's market dominance lies in its proven effectiveness for patients with B-cell lymphomas, particularly in relapsed or refractory cases where traditional treatments often fall short. As more patients seek alternatives for aggressive forms of cancer, the demand for Yescarta continues to grow, further cementing its leadership in the space.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $4.3 Billion |
Forecast Value | $61.1 Billion |
CAGR | 30.5% |
In terms of indications, the CAR T-cell therapy market is categorized into leukemia, lymphoma, multiple myeloma, and others, with lymphoma generating the highest revenue of USD 2.4 billion in 2024. Diffuse large B-cell lymphoma (DLBCL), a common form of non-Hodgkin lymphoma is a major contributor to this growth. DLBCL's high relapse rates following conventional therapies have driven demand for CAR T-cell treatments, which have shown remarkable efficacy in targeting and treating aggressive lymphoma. As a result, CAR T-cell therapies are increasingly viewed as a vital solution in managing these challenging cancer types, offering new hope to patients with few options left.
The U.S. CAR T-cell therapy market is expected to reach USD 25 billion by 2034, with strong growth fueled by supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has played a key role in the rapid development and commercialization of CAR T-cell therapies, providing critical regulatory support through expedited approval processes such as Breakthrough Therapy Designations, Orphan Drug status, and Fast Track pathways. These initiatives have fast-tracked the availability of CAR T-cell therapies, ensuring timely access for patients in need of life-saving treatments.